Immunocore Holdings Plc (IMCR)
30.98
-1.14
(-3.55%)
USD |
NASDAQ |
Oct 23, 16:00
31.07
+0.09
(+0.29%)
After-Hours: 20:00
Immunocore Holdings Enterprise Value : 1.150B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 1.150B |
| October 22, 2026 | 1.208B |
| October 21, 2026 | 1.207B |
| October 20, 2026 | 1.233B |
| October 19, 2026 | 1.091B |
| October 16, 2026 | 1.068B |
| October 15, 2026 | 1.072B |
| October 14, 2026 | 1.014B |
| October 13, 2026 | 986.93M |
| October 12, 2026 | 1.050B |
| October 09, 2026 | 1.068B |
| October 08, 2026 | 1.052B |
| October 07, 2026 | 1.069B |
| October 06, 2026 | 1.076B |
| October 05, 2026 | 1.078B |
| October 02, 2026 | 1.084B |
| October 01, 2026 | 1.127B |
| September 30, 2026 | 1.114B |
| September 29, 2026 | 1.143B |
| September 28, 2026 | 1.132B |
| September 25, 2026 | 1.136B |
| September 24, 2026 | 1.166B |
| September 23, 2026 | 1.178B |
| September 22, 2026 | 1.224B |
| September 21, 2026 | 1.211B |
| Date | Value |
|---|---|
| September 18, 2026 | 1.202B |
| September 17, 2026 | 1.218B |
| September 16, 2026 | 1.181B |
| September 15, 2026 | 1.191B |
| September 14, 2026 | 1.226B |
| September 11, 2026 | 1.233B |
| September 10, 2026 | 1.283B |
| September 09, 2026 | 1.329B |
| September 08, 2026 | 1.375B |
| September 04, 2026 | 1.415B |
| September 03, 2026 | 1.489B |
| September 02, 2026 | 1.479B |
| September 01, 2026 | 1.452B |
| August 31, 2026 | 1.425B |
| August 28, 2026 | 1.440B |
| August 27, 2026 | 1.447B |
| August 26, 2026 | 1.466B |
| August 25, 2026 | 1.480B |
| August 24, 2026 | 1.439B |
| August 21, 2026 | 1.453B |
| August 20, 2026 | 1.422B |
| August 19, 2026 | 1.452B |
| August 18, 2026 | 1.409B |
| August 17, 2026 | 1.359B |
| August 14, 2026 | 1.316B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Silence Therapeutics Plc | 830.94M |
| Biodexa Pharmaceuticals Plc | -- |
| NuCana Plc | -20.75M |
| Mereo BioPharma Group Plc | 15.88M |
| Compass Pathways Plc | 1.138B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.8095M |
| Revenue (Quarterly) | 116.14M |
| Total Expenses (Quarterly) | 116.95M |
| EPS Diluted (Quarterly) | -0.0159 |
| Gross Profit Margin (Quarterly) | 98.18% |
| Profit Margin (Quarterly) | -0.70% |
| Earnings Yield | -1.19% |
| Normalized Earnings Yield | -1.827 |